regulatory approval

News

Dupixent claims new territory in eosinophilic oesophagitis

Sanofi and Regeneron have added another string to the bow of their immunology blockbuster Dupixent with an FDA approval in eosinophilic oesophagitis (EoE), which could help the drug reach i

News

Takeda spinout Phathom claims its first FDA approvals

Three years after it was formed as a spinout of Japanese drugmaker Takeda, Phathom Pharmaceuticals has racked up its first FDA approvals, and claimed a sizeable $260 million in new financin

News

Illustration of the thought processes in the brain

FDA approves first in vitro test for early Alzheimer's disea...

The US FDA has authorised a new test that can detect amyloid plaques in early-stage Alzheimer's disease without the use of PET scans, which expose patients to radiation.

News

Kymriah is first CAR-T cleared for follicular lymphoma in EU

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

News

Idorsia is first to EU market with orexin insomnia drug

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and

News

BMS bags FDA okay for cardiomyopathy drug mavacamten

Bristol-Myers Squibb's has become the first company to bring a cardiac myosin inhibitor through to FDA approval, claiming a green light from the US regulator for mavacamten as a therapy for

Dupixent claims new territory in eosinophilic oesophagitis

Takeda spinout Phathom claims its first FDA approvals

FDA approves first in vitro test for early Alzheimer's disea...

Kymriah is first CAR-T cleared for follicular lymphoma in EU

Idorsia is first to EU market with orexin insomnia drug

BMS bags FDA okay for cardiomyopathy drug mavacamten

Getting predictive technologies to patients, with Concr

Discover a new era of healthcare panel engagement: Grounded ...

regulatory approval

Editor's Picks